In a correspondence published in Angiogenesis, researchers Güney Sarıoğlu and Oğuz Kaan Kaya evaluated long-term follow-up findings regarding angiogenic and thromboinflammatory biomarkers in survivors of severe or critical COVID-19. The underlying longitudinal study by Mora Zetina and colleagues gathered paired biological measurements during initial acute hospitalization and again approximately 3.5 years later. The persistent elevation of specific circulating factors—including vascular endothelial growth factor D (VEGF-D), angiopoietin-1, and α2-macroglobulin—supports continued investigation into long-term vascular abnormalities associated with post-COVID-19 syndrome. However, the authors emphasized that investigators must carefully distinguish sustained biomarker elevation from conclusive proof of ongoing pathological activity.
Although the longitudinal design showed that selected circulating markers remained abnormal relative to acute trajectories over more than three years, interpreting these late measurements remains challenging due to the absence of a contemporaneous reference group. Without age-matched and comorbidity-matched control participants who never experienced COVID-19, or ideally recovered COVID-19 survivors who did not develop persistent symptoms, researchers cannot determine what these elevated readings truly reflect. Consequently, the measurements might represent persistent virus-related vascular dysregulation, pre-existing differences between individuals, residual effects from severe acute illness, or background cardiometabolic and inflammatory health conditions.
Sarıoğlu and Kaya highlighted that the biological specificity of the identified markers is a key factor limiting interpretation. Signaling molecules such as VEGF-D and angiopoietin-1 are not unique to post-COVID vascular damage; instead, they play broad physiological roles in maintaining endothelial homeostasis, guiding vascular remodeling, regulating inflammation, and facilitating tissue repair. Because these proteins participate in diverse biological responses, the prolonged presence of an abnormal concentration does not prove that the initial mechanism active during acute SARS-CoV-2 infection persists. Over several years, a biomarker can remain elevated while its underlying pathophysiological meaning shifts considerably.
This distinction carries direct consequences for understanding patient symptoms and attributing cause in clinical studies. Participants in the follow-up cohort frequently experienced ongoing symptoms such as fatigue, shortness of breath, and concentration difficulties. Nevertheless, the mere coexistence of physical symptoms alongside circulating biomarker abnormalities does not establish that the measured vascular pathways directly mediate those clinical complaints. The underlying biology of post-COVID-19 syndrome is highly heterogeneous and likely involves multiple overlapping processes, including endothelial dysfunction, broad immune dysregulation, autonomic nervous system abnormalities, viral persistence, and microvascular tissue injury.
Because of these overlapping mechanisms, biomarker elevations may characterize a broader biological phenotype without serving as disease-specific mechanistic markers. To advance beyond these observational limitations and clarify underlying relationships, the authors recommended comparing long-term biomarker levels across at least three distinct clinical cohorts. These groups should include individuals suffering from persistent post-COVID symptoms, fully recovered COVID-19 survivors who remain completely symptom-free, and matched control subjects without any prior SARS-CoV-2 infection.
In addition to multi-group cohort comparisons, serial testing across the recovery timeline would determine whether circulating markers display sustained elevation, delayed normalization, or secondary re-emergence. Correlating these longitudinal biomarker trajectories with objective vascular measurements and clinical outcomes would substantially strengthen causal interpretations. Although the data from Mora Zetina and colleagues provide valuable insight across a follow-up duration rarely documented in post-COVID biomarker research, the findings are best interpreted as evidence of a persistent vascular biomarker signature rather than definitive confirmation of continuously active vascular pathology.
Clarifying whether these biological signals reflect continuous disease activity or an evolving molecular signature remains essential before clinicians and researchers incorporate the candidate markers into formal clinical practice. The authors concluded that establishing this fundamental distinction will be critically necessary prior to integrating VEGF-D, angiopoietin-1, or α2-macroglobulin into disease-specific mechanistic models, clinical risk stratification frameworks, or therapeutic response monitoring programs for post-COVID-19 syndrome.
Subject of Research: Post-COVID-19 syndrome and long-term vascular biomarker persistence
Article Title: From persistent biomarker signatures to vascular pathophysiology in post-COVID-19 syndrome
Article References: Sarıoğlu, G., & Kaya, O. K. (2026). From persistent biomarker signatures to vascular pathophysiology in post-COVID-19 syndrome. Angiogenesis, 29(4), Article 80. https://doi.org/10.1007/s10456-026-10099-9
Image Credits: AI Generated
DOI: 10.1007/s10456-026-10099-9
Keywords: post-COVID-19 syndrome, long COVID, vascular biomarkers, VEGF-D, angiopoietin-1, alpha-2-macroglobulin, endothelial dysfunction, thromboinflammation, angiogenesis, microvascular injury, severe COVID-19, longitudinal follow-up, fatigue, dyspnea, concentration difficulties, vascular pathophysiology, endothelial homeostasis, tissue repair
News Source: Drew Townsend. (November 21, 2026). Persistent Post-COVID Vascular Biomarkers May Not Indicate Ongoing Active Pathology. Scienmag.



